Nantahala Capital Management’s Bioventus BVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$56.6M Sell
6,000,279
-122,124
-2% -$1.17M 1.88% 8
2026
Q1
$55.9M Buy
6,122,403
+75,000
+1% +$629K 2.06% 9
2025
Q4
$45M Buy
6,047,403
+236,741
+4% +$1.7M 1.49% 14
2025
Q3
$38.9M Buy
5,810,662
+529,820
+10% +$3.68M 1.35% 17
2025
Q2
$35M Buy
5,280,842
+1,155,192
+28% +$8.19M 1.37% 13
2025
Q1
$37.7M Buy
4,125,650
+98,841
+2% +$987K 1.5% 12
2024
Q4
$42.3M Sell
4,026,809
-324,061
-7% -$3.83M 1.82% 11
2024
Q3
$52M Sell
4,350,870
-987,444
-18% -$8.54M 2.63% 7
2024
Q2
$30.7M Sell
5,338,314
-467,698
-8% -$2.57M 1.79% 10
2024
Q1
$30.2M Sell
5,806,012
-171,459
-3% -$838K 1.72% 12
2023
Q4
$31.5M Sell
5,977,471
-41,061
-0.7% -$162K 1.88% 9
2023
Q3
$19.9M Buy
6,018,532
+400,906
+7% +$1.41M 1.7% 14
2023
Q2
$16.2M Buy
5,617,626
+444,157
+9% +$852K 1.57% 13
2023
Q1
$5.54M Buy
5,173,469
+2,004,895
+63% +$3.84M 0.42% 47
2022
Q4
$8.27M Buy
3,168,574
+2,789,735
+736% +$12.2M 0.54% 40
2022
Q3
$2.65M Buy
+378,839
New +$2.97M 0.17% 68

Other funds holding BVS

Nantahala Capital Management's BVS Position: Q2 2026 in Review

Nantahala Capital Management reduced its Bioventus (BVS) stake by 2% in Q2 2026, selling an estimated $1.17M and leaving 6,000,279 shares worth $56.6M. The position accounts for 1.88% of the portfolio, ranked #8.

Nantahala Capital Management first reported a position in BVS in Q3 2022 and has held it in 16 quarters since. 157 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

  • Nantahala Capital Management held 6,000,279 shares of Bioventus worth $56.6M as of Q2 2026.
  • Nantahala Capital Management sold 122,124 Bioventus shares in Q2 2026, an estimated $1.17M.
  • Bioventus made up 1.88% of Nantahala Capital Management's portfolio in Q2 2026, its #8 holding.
  • Nantahala Capital Management first reported a position in Bioventus in Q3 2022 and has held it in 16 quarters since.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.